[1]汪明阳,曹忠超,王艳超,等.甲状腺癌组织中KDM1A和UCHL3的表达与临床病理学特征及预后的关系研究[J].现代检验医学杂志,2025,40(01):105-109+115.[doi:10.3969/j.issn.1671-7414.2025.01.020]
　WANG Mingyang,CAO Zhongchao,WANG Yanchao,et al.Study on the Expression of KDM1A and UCHL3 in Thyroid Cancer Tissue and Relationship with the Clinical Pathological Features and Prognosis[J].Journal of Modern Laboratory Medicine,2025,40(01):105-109+115.[doi:10.3969/j.issn.1671-7414.2025.01.020]
点击复制

甲状腺癌组织中KDM1A和UCHL3的表达与临床病理学特征及预后的关系研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第40卷
期数:
2025年01期
页码:
105-109+115
栏目:
论著
出版日期:
2025-01-15

文章信息/Info

Title:
Study on the Expression of KDM1A and UCHL3 in Thyroid Cancer Tissue and Relationship with the Clinical Pathological Features and Prognosis
文章编号:
1671-7414（2025）01-105-06
作者:
汪明阳; 曹忠超; 王艳超; 刘春秀
（黑龙江省第三医院普外科，黑龙江北安 164000）
Author(s):
WANG Mingyang; CAO Zhongchao; WANG Yanchao; LIU Chunxiu
(Department of General Surgery，the Third Hospital of Heilongjiang Province, Heilongjiang Bei’an 164000，China)
关键词:
甲状腺癌; 组蛋白赖氨酸脱甲基酶1; 泛素羧基末端水解酶L3
分类号:
R736.1；R730.43
DOI:
10.3969/j.issn.1671-7414.2025.01.020
文献标志码:
A
摘要:
目的 研究甲状腺癌（TC）组织中组蛋白赖氨酸脱甲基酶1(KDM1A)、泛素羧基末端水解酶L3(UCHL3) 表达与临床病理学特征及预后的关系。方法 回顾性收集2017 年1 月～ 2019 年1 月黑龙江省第三医院诊治的94 例TC 患者为研究对象。采用免疫组织化学检测组织KDM1A，UCHL3 的表达；采用Spearman 相关性分析KDM1A 与UCH-L3的相关性；采用Kaplan-Meier 生存曲线分析KDM1A，UCHL3 与患者五年无进展生存率的关系，多因素COX 回归模型分析TC 患者预后的影响因素。结果 癌组织中KDM1A（68.09%），UCH L3（65.96%）阳性率高于癌旁组织（10.64%，8.51%），差异具有统计学意义（χ2=64.984，66.369，均P ＜ 0.001）。Spearman 相关性分析，KDM1A 与UCH L3 蛋白表达呈显著正相关（r=0.714，P ＜ 0.001）。TNM 分期III ～ IV 期、淋巴结转移TC 癌组织中KDM1A（87.50%，90.91%），UCH L3（85.00%，87.88%）阳性率高于I ～ II 期（53.70%，53.85%）、无淋巴结转移癌组织（55.74%，54.10%），差异具有统计学意义（χ2=9.985 ～ 12.191，均P<0.05）。KDM1A 阳性组和阴性组TC 患者五年无进展生存率分别为62.50%（40/64），86.67%（26/30），UCH L3 阳性组和阴性组患者五年无进展生存率分别为58.06%（36/62），90.63%（29/32），差异具有统计学意义（Log-Rankχ2=5.670，9.724，P=0.017，0.002）。KDM1A 阳性、UCH L3 阳性、TNM 分期Ⅲ～Ⅳ期、淋巴结转移是影响TC 患者预后的危险因素（Waldχ2=1.315 ～ 1.697，均P ＜ 0.001）。结论 TC中KDM1A，UCH L3 表达上调，均在TC 中发挥促癌作用，是新的评估TC 患者预后的肿瘤标志物。
Abstract:
Objective The purpose of this study is to investigate the expression of histone lysine-specific demethylase 1 (KDM1A) and ubiquitin carboxyl-terminal hydrolase L3 (UCHL3) in thyroid cancer (TC) tissue and its relationship with clinical features and prognosis. Methods 94 TC patients diagnosed and treated at the Third Hospital of Heilongjiang Province from January 2017 to January 2019 were retrospectively selected as the study subjects. Immunohistochemistry was used to detect the expression of KDM1A and UCHL3 in tissues. Spearman correlation analysis was used to investigate the correlation between KDM1A and UCHL3. Kaplan-Meier survival curve was used to analyze the relationship between the levels of KDM1A and UCHL3 and the 5-year progression-free survival rate of TC patients. Multivariate COX regression model was used to analyze the prognostic factors of TC patients. Results The positive rates of KDM1A (68.09%) and UCHL3 (65.96%) in cancer tissues were higher than those in adjacent tissues（10.64%，8.51%）, and the differences were statistically significant(χ2=64.984，66.369，all P ＜ 0.001). The protein expression of KDM1A and UCHL3 was significant protein correlation (r=0.714，P<0.001). The positive rates of KDM1A (87.50%，90.91%) and UCHL3 (85.00%，87.88%) in TNM stage III ～ IV and lymph node metastatic TC cancer tissues were higher than those in stage I ～ II（53.70%，53.85%）and non-lymph node metastatic（55.74%，54.10%） cancer tissues，and the differences were statistically significant（χ2=9.985 ～ 12.191，all P ＜ 0.001). The 5-year progressionfree survival rates of TC patients in the KDM1A positive and negative groups were 62.50% (40/64) and 86.67% (26/30), with significant differences ，the 5-year progression-free survival rates of UCH L3 positive and negative patients were 58.06% (36/62) and 90.63% (29/32), with significant differences （Log-Rankχ2=5.670，9.724，P=0.017，0.002）. KDM1A positive , UCH L3 positive, TNM stage III ～ IV , lymph node metastasis were risk factors affecting the prognosis of TC patients （Waldχ2=1.315 ～1.697,all P ＜ 0.001）. Conclusion KDM1A and UCHL3 are upregulated in TC, and played a pro-cancer role. They are new tumor markers for evaluating the prognosis of TC patients.

参考文献/References:

[1] PIZZATO M，LI Mengmeng, VIGNAT J, et al. The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020[J]. the Lancet-Diabetes & Endocrinology, 2022, 10(4): 264-272.
[2] 仲亚东, 孔德桐, 马伯敏. 甲状腺癌患者组织及手术前后血清中NR3C2 和ZEB1 表达水平及其与预后价值研究[J]. 现代检验医学杂志,2023,38(4):94-99． ZHONG Yadong, KONG Detong, MA Baimin. Study on the expression level of NR3C2 and ZEB1 in thyroid cancer tissue and serum of patients before and after surgery and their prognostic value[J].Journal of Modern Laboratory Medicine, 2023, 38(4): 94-99.
[3] LEE D Y, SALAHUDDIN T, IQBAL J. Lysine-specific demethylase 1(LSD1)-mediated epigenetic modification of immunogenicity and immunomodulatory effects in breast cancers[J].Current Oncology (Toronto, Ont.), 2023, 30(2): 2127-2143.
[4] YANG Hanjie, LIU Tian, XIONG Yang. Anti-cancer effect of LINC00478 in bladder cancer correlates with KDM1A-dependent MMP9 demethylation[J]. Cell Death Discovery, 2022, 8(1): 242.
[5] HEWITT C S, DAS C, FLAHERTY D P. Rational development and characterization of a ubiquitin variant with selectivity for ubiquitin C-terminal hydrolase L3[J]. Biomolecules, 2022, 12(1): 62.
[6] ZHANG Yuan, LIU Jingbo, LIU Jing, et al. UCHL3 promotes cervical cancer development and metastasis by stabilizing NRF2 via deubiquitination [J]. Biochemical and Biophysical Research Communications, 2023, 641: 132-138.
[7] 徐志勇, 马晓良. 甲状腺癌患者术后复发风险预测的列线图模型建立[J]. 实用肿瘤学杂志,2021,35(1):35-40. XU Zhiyong, MA Xiaoliang. Establishment of a nomogram model for predicting the risk of postoperative recurrence in patients with thyroid cancer[J]. Practical Oncology Journal, 2021, 35(1): 35-40.
[8] ZHANG Chaofeng, WANG Zhiyuan, SHI Yuting, et al. Recent advances of LSD1/KDM1A inhibitors for disease therapy [J]. Bioorganic Chemistry, 2023, 134: 106443.
[9] KARAKAIDOS P, VERIGOS J, MAGKLARA A. LSD1/KDM1A, a gatekeeper of cancer stemness and a promising therapeutic target[J]. Cancers, 2019, 11(12): 1821.
[10] DING Xiaoling, ZHANG Jie, FENG Ziqin, et al. MiR-137-3p inhibits colorectal cancer cell migration by regulating a KDM1A-dependent epithelial-mesenchymal transition[J]. Digestive Diseases and Sciences, 2021, 66(7): 2272-2282.
[11] ZHANG Wei, RUAN Xianhui, LI Yaoshuang, et al. KDM1A promotes thyroid cancer progression and maintains stemness through the Wnt/β-catenin signaling pathway[J]. Theranostics, 2022, 12(4): 1500-1517.
[12] LU Can, CAI Yuan, LIU Wei, et al. Aberrant expression of KDM1A inhibits ferroptosis of lung cancer cells through up-regulating c-Myc[J]. Scientific Reports, 2022, 12(1): 19168.
[13] ALEJO S, PALACIOS B E, VENKATA P P, et al. Lysinespecific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double-strand break repair and augments the efficacy of temozolomide in glioblastoma[J]. Neuro-Oncology, 2023, 25(7): 1249-1261.
[14] LI Guoping, JIN Xiaosheng, ZHENG Jisheng, et al.UCH-L3 promotes non-small cell lung cancer proliferation via accelerating cell cycle and inhibiting cel l apoptosis[J].Biotechnology and Applied Biochemistry, 2021, 68(1): 165-172.
[15] ZHANG Minghui, ZHANG Huihui, DU Xuehua, et al.UCH L3 promotes ovarian cancer progression by stabilizing TRAF2 to activate the NF-κB pathway[J]. Oncogene, 2020, 39(2): 322-333.
[16] TANG Jianing, YANG Qian, MAO Chao, et al. The deubiquitinating enzyme UCH L3 promotes anaplastic thyroid cancer progression and metastasis through Hippo signaling pathway[J]. Cell Death and Differentiation, 2023, 30(5): 1247-1259.
[17] XU Liming, YUAN Yajing, YU Hao, et al. LINC00665 knockdown confers sensitivity in irradiated non-small cell lung cancer cells through the miR-582-5p/UCH L3/AhR axis[J]. Journal of Translational Medicine, 2022, 20(1): 350.
[18] FAN Y, HU D, LI D, et al. UCH L3 promotes aerobic glycolysis of pancreatic cancer through upregulating LDHA expression[J].Clinical and Translational Oncology, 2021, 23(8): 1637-1645.
[19] LIU Miaowen, CHEN Huimin, CHEN Xinyue, et al. Silencing UCH L3 enhances radio-sensitivity of nonsmall cell lung cancer cells by inhibiting DNA repair[J]. Aging (Albany NY), 2021, 13(10): 14277-14288.
[20] MA Qiancheng, LU Qiliang, LEI Xiangxiang, et al.UCHL3 promotes hepatocellular carcinoma cell migration by de-ubiquitinating and stabilizing vimentin [J]. Frontiers in Oncology, 2023, 13: 1088475.

相似文献/References:

[1]彭继英a,杨红杰b,石晓欣a,等.细针穿刺细胞学检查在甲状腺癌碘-131 治疗后复发诊断中的应用价值[J].现代检验医学杂志,2020,35(01):127.[doi:10.3969/j.issn.1671-7414.2020.01.033]
　PENG Ji-yinga,YANG Hong-jieb,SHI Xiao-xina,et al.Application Value of Fine Needle Aspiration Cytology in Recurrence Diagnosis of Thyroid Cancer after Iodine-131 Treatment[J].Journal of Modern Laboratory Medicine,2020,35(01):127.[doi:10.3969/j.issn.1671-7414.2020.01.033]
[2]赵芳芳,郭　红,陈　嘉.LncRNA TUG1 在甲状腺癌组织中的表达及其对细胞增殖和迁移的影响[J].现代检验医学杂志,2020,35(06):42.[doi:doi:10.3969/j.issn.1671-7414.2020.06.011]
　ZHAO Fang-fang,GUO Hong,CHEN Jia.Expression of LncRNA TUG1 in Thyroid Carcinoma Tissues and Its Effect onCell Proliferation and Migration[J].Journal of Modern Laboratory Medicine,2020,35(01):42.[doi:doi:10.3969/j.issn.1671-7414.2020.06.011]
[3]仲亚东,孔德桐,马伯敏.甲状腺癌患者组织及手术前后血清中NR3C2 和ZEB1 表达水平及其与预后价值研究[J].现代检验医学杂志,2023,38(04):94.[doi:10.3969/j.issn.1671-7414.2023.04.017]
　ZHONG Yadong,KONG Detong,MA Bomin.Study on the Expression Level of NR3C2 and ZEB1 in Thyroid Cancer Tissue and Serum of Patients before and after Surgery and Their Prognostic Value[J].Journal of Modern Laboratory Medicine,2023,38(01):94.[doi:10.3969/j.issn.1671-7414.2023.04.017]
[4]谈玖婷,傅聿明,刘 婧,等.甲状腺癌组织中DCBLD2 和MAP4K3 的表达及与临床病理特征及预后的关系[J].现代检验医学杂志,2024,39(02):34.[doi:10.3969/j.issn.1671-7414.2024.02.007]
　TAN Jiuting,FU Yuming,LIU Jing,et al.Expression of DCBLD2 and MAP4K3 in Thyroid Cancer Tissue and Their Relationship with Clinico-pathological Features and Prognosis[J].Journal of Modern Laboratory Medicine,2024,39(01):34.[doi:10.3969/j.issn.1671-7414.2024.02.007]
[5]张廷华a,胡友元b,袁 博.miR-100-5p 对甲状腺癌细胞增殖与凋亡调控作用的实验研究[J].现代检验医学杂志,2024,39(04):56.[doi:10.3969/j.issn.1671-7414.2024.04.011]
　ZHANG Tinghuaa,HU Youyuanb,YUAN Bo.Experimental Study on the Regulatory Effects of miR-100-5p on Proliferation and Apoptosis of Thyroid Cancer Cells[J].Journal of Modern Laboratory Medicine,2024,39(01):56.[doi:10.3969/j.issn.1671-7414.2024.04.011]

备注/Memo

备注/Memo:
基金项目：黑龙江省卫生健康委科研课题（20210505010044）。
作者简介：汪明阳（1988-），男，本科，主治医师，研究方向：普外科，E-mail：wangmingyang7890@163.com。
通讯作者：刘春秀，女，硕士研究生，副主任医师，研究方向：口腔医学，E-mail：364568957@qq.com。
更新日期/Last Update: 2025-01-15